# US 2021/0079397 A1 · Nucleic acid linked to a trivalent glycoconjugate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079397 A1
- Document ID: US20210079397A1
- Status: Published application
- Kind: A1
- Application number: 17/104,502
- Filed: 2020-11-25
- Published: 2021-03-18
- Earliest claimed: 2016-04-05
- Assignees: Silence Therapeutics GmbH
- Applicants: Silence Therapeutics GmbH
- Inventors: Christian Frauendorf; Mark Cameron
- Web page: https://patentgrep.com/patent/US20210079397A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/56: the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/351: Conjugate
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a compound comprising a modified saccharide moiety conjugated to a nucleic acid. The compound is useful in medicine for RNA interference therapy or for research and diagnostic purposes. In particular, the compound is useful in treating liver disease.

## Claims

### Claim 1

A compound having the formula (I):
[S—X1—P—X2]3-A-X3—Z (I)
wherein:
S represents a saccharide;
X1 represents C3-C6 alkylene or an ethylene glycol stem (—CH2—CH2—O)m(—CH2)2— wherein m is 1, 2, or 3;
P is a modified phosphate;
X2 is alkylene or an alkylene ether of the formula (—CH2)n—O—CH2— where n=1-6;
A is a branching unit;
X3 represents a bridging unit;
Z is a nucleic acid;
and where the linkage between X3 and Z is a phosphate or thiophosphate.

### Claim 2 (depends on 1)

A compound of claim 1, wherein the compound is of formula (II):
[S—X1—P—X2]3-A-X3—Z (II)
wherein:
S represents a saccharide;
X1 represents C3-C6 alkylene or an ethylene glycol stem (—CH2—CH2—O)m(—CH2)2— wherein
m is 1, 2, or 3;
P is a modified phosphate;
X2 is C1-C8 alkylene;
A is a branching unit selected from:
X3 is a bridging unit;
Z is a nucleic acid;
and where the linkage between X3 and Z is a phosphate or thiophosphate.

### Claim 3 (depends on 2)

A compound according to claim 2, wherein A has the structure:

### Claim 4 (depends on 2)

A compound according to claim 2, wherein A has the structure:
wherein X3 is attached to the nitrogen atom.

### Claim 5 (depends on 1)

A compound according to claim 1, wherein X3 is selected from —C1-C20 alkylene-, —C2-C20 alkenylene-, an alkylene ether of formula —(C1-C20 alkylene)-O—(C1-C20 alkylene)-, —C(O)—C1-C20 alkylene-, —C0-C4 alkylene(Cy)C0-C4 alkylene- wherein Cy represents a substituted or unsubstituted 5 or 6 membered cycloalkylene, arylene, heterocyclylene or heteroarylene ring, —C1-C4 alkylene-NHC(O)—C1-C4 alkylene-, —C1-C4 alkylene-C(O)NH—C1-C4 alkylene-, —C1-C4 alkylene-SC(O—)C1-C4 alkylene-, —C1-C4 alkylene-C(O)S—C1-C4 alkylene-, —C1-C4 alkylene-OC(O)—C1-C4 alkylene-, —C1-C4 alkylene-C(O)O—C1-C4 alkylene-, and —C1-C6 alkylene-S—S—C1-C6 alkylene-.

### Claim 6 (depends on 5)

A compound according to claim 5, wherein X3 is an alkylene ether of formula —(C1-C20 alkylene)-O—(C1-C20 alkylene)-.

### Claim 7 (depends on 6)

A compound according to claim 6, wherein X3 is an alkylene ether of formula —(C1-C20 alkylene)-O—(C4-C20 alkylene)-, wherein said (C4-C20 alkylene) is linked to Z.

### Claim 8 (depends on 6)

A compound according to claim 6, wherein X3 is selected from the group consisting of —CH2—O—C3H6—, —CH2—O—C4H8—, —CH2—O—C6H12— and —CH2—O—C8H16—, especially —CH2—O—C4H8—, —CH2—O—C6H12— and —CH2—O—C8H16—, wherein in each case the —CH2— group is linked to A.

### Claim 9 (depends on 2)

A compound according to claim 2, wherein X3 is C1-C20 alkylene.

### Claim 10 (depends on 9)

A compound according to claim 9, wherein X3 is selected from the group consisting of —C3H6—, —C4H8—, —C6H12— and —C8H16—, especially —C4H8—, —C6H12— and —C8H16—.

### Claim 11 (depends on 1)

A compound of claim 1, wherein the compound is of formula (III)
[S—X1—P—X2]3-A-X3—Z (III)
wherein:
S represents a saccharide;
X1 represents C3-C6 alkylene or an ethylene glycol stem (—CH2—CH2—O)m(—CH2)2— wherein m is 1, 2, or 3;
P is a modified phosphate;
X2 is an alkylene ether of formula —C3H6—O—CH2—;
A is a branching unit;
X3 is an alkylene ether of formula selected from the group consisting of —CH2—O—CH2—, —CH2—O—C2H4—, —CH2—O—C3H6—, —CH2—O—C4H8—, —CH2—O—C5H10—, —CH2—O—C6H12—, —CH2—O—C7H14—, and —CH2—O—C8H16—, wherein in each case the —CH2— group is linked to A;
Z is a nucleic acid;
and wherein the linkage between X3 and Z is a phosphate or thiophosphate.

### Claim 12 (depends on 11)

A compound according to claim 11, wherein the branching unit comprises carbon.

### Claim 13 (depends on 12)

A compound according to claim 12, wherein the branching unit is a carbon atom.

### Claim 14 (depends on 11, 12, 13)

A compound according to any of claims 11 to 13, wherein X3 is selected from the group consisting of —CH2—O—C4H8—, —CH2—O—C5H10—, —CH2—O—C6H12—, —CH2—O—C7H14—, and —CH2—O—C8H16—.

### Claim 15 (depends on 14)

A compound according to claim 14, wherein X3 is selected from the group consisting of —CH2—O—C4H8—, —CH2—O—C6H12— and —CH2—O—C8H16—.

### Claim 16

A compound according to any preceding claim, wherein the modified phosphate is a thiophosphate.

### Claim 17

A compound according to any preceding claim, wherein the saccharide is selected from N-acetyl galactosamine, mannose, galactose, glucose, glucosamine and fructose.

### Claim 18 (depends on 17)

A compound according to claim 17, wherein the saccharide is N-acetyl galactosamine.

### Claim 19

A compound according to any preceding claim, wherein X1 is an ethylene glycol stem (—CH2—CH2—O)m(—CH2)2— wherein m is 1, 2, or 3.

### Claim 20

A compound according to any preceding claim, wherein X1 represents C3-C6 alkylene.

### Claim 21

A compound of formula:
wherein Z is a nucleic acid.

### Claim 22

A compound of formula:
wherein Z is a nucleic acid.

### Claim 23

A compound of formula:
wherein Z is a nucleic acid.

### Claim 24

A compound of formula:
wherein Z is a nucleic acid.

### Claim 25

A compound of formula:
wherein Z is a nucleic acid.

### Claim 26

A compound of formula:
wherein Z is a nucleic acid.

### Claim 27

A compound of formula:
wherein Z is a nucleic acid.

### Claim 28

A compound of formula:
wherein Z is a nucleic acid.

### Claim 29

A compound according to any preceding claim, wherein the nucleic acid is selected from RNAi, siRNA, antisense nucleic acid, ribozymes, aptamers and spiegelmers.

### Claim 30

A compound according to any preceding claim, wherein the nucleic acid is modified.

### Claim 31 (depends on 30)

A compound according to claim 30, wherein the modification is selected from substitutions or insertions with analogues of nucleic acids or bases and chemical modification of the base, sugar or phosphate moieties.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A composition comprising a compound as defined in any one of claims 1 to 31 and a suitable carrier or excipient.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A compound as defined in any one of claims 1 to 31, or a composition as defined in claim 32, for use in medicine.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A compound as defined in any one of claims 1 to 31, or a composition as defined in claim 32, for use in the treatment of liver diseases, genetic diseases, hemophilia and bleeding disorders, liver fibrosis, non-alcoholic steotohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), viral hepatitis, rare diseases (e.g. acromegaly), metabolic diseases (e.g. hypercholesterolemia, dyslipidemia, hypertriglyceridemia), cardiovascular diseases, obesity, thalassemia, liver injury (e.g. drug induced liver injury), hemochromatosis, alcoholic liver diseases, alcohol dependence, anemia, and anemia of chronic diseases.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A method of delivery of nucleic acids to hepatocytes comprising contacting the hepatocyte with a compound according to any one of claims 1 to 31.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A process for making a compound of formula (I) as claimed in any one of claims 1 to 31, the process comprising adding together each component to form the compound of formula (I).
